StreetInsider.com News Articles

Join Today's Live Investor Webinar with TransCode Therapeutics

Wed, 16 Sep 2026 09:00:00 -0400

Learn how TransCode Therapeutics is advancing RNA therapeutics, cancer vaccines, and immuno-oncology programs designed to address advanced and metastatic cancers

Management to discuss TTX-MC138, the ongoing Phase 2a colorectal cancer trial, tumor-targeted RNA delivery, and multiple upcoming clinical catalysts

ORLANDO, FL / ACCESS Newswire / September 16, 2026 / RedChip Companies will host an investor webinar today, September 16, 2026, at 4:15 p.m. ET with TransCode Therapeutics, Inc. (NASDAQ:RNAZ). The webinar is free to attend and open to all.

The exclusive event will feature Philippe P. Calais Ph.D., Chairman and CEO; Zdravka Medarova, Ph.D.,

Join Today's Live Investor Webinar with TransCode Therapeutics

Wed, 16 Sep 2026 09:00:00 -0400

Learn how TransCode Therapeutics is advancing RNA therapeutics, cancer vaccines, and immuno-oncology programs designed to address advanced and metastatic cancers

Management to discuss TTX-MC138, the ongoing Phase 2a colorectal cancer trial, tumor-targeted RNA delivery, and multiple upcoming clinical catalysts

The exclusive event will feature Philippe P. Calais Ph.D., Chairman and CEO; Zdravka Medarova, Ph.D.,

Form 4 Transcode Therapeutics, For: Sep 09 Filed by: Fitzgerald Thomas A

Fri, 11 Sep 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260911/27053637.html

Form 8-K Transcode Therapeutics, For: Sep 09

Fri, 11 Sep 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260911/27053564.html

TransCode Therapeutics CFO Tom Fitzgerald retires, replaced interim

Thu, 10 Sep 2026 16:13:02 -0400

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced the retirement of Chief Financial Officer Tom Fitzgerald, effective immediately, with John Tattory named as Interim Chief Financial Officer.

Fitzgerald has served as CFO since July 2018, during which time he helped lead the company through its initial public offering, the launch of its clinical program for lead product candidate TTX-MC138, and the acquisition of Polynoma and a license agreement with Oncolytics.

Philippe P. Calais, Ph.D., Chairman of the Board and CEO, said: "On behalf of the Board, I wish to thank Tom for his many years of dedicated service to the company and its key

TransCode Therapeutics CFO Tom Fitzgerald retires, replaced interim

Thu, 10 Sep 2026 16:13:02 -0400

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced the retirement of Chief Financial Officer Tom Fitzgerald, effective immediately, with John Tattory named as Interim Chief Financial Officer.

Philippe P. Calais, Ph.D., Chairman of the Board and CEO, said: "On behalf of the Board, I wish to thank Tom for his many years of dedicated service to the company and its key

TransCode Therapeutics CFO Tom Fitzgerald retires, replaced interim

Thu, 10 Sep 2026 16:13:02 -0400

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced the retirement of Chief Financial Officer Tom Fitzgerald, effective immediately, with John Tattory named as Interim Chief Financial Officer.

Philippe P. Calais, Ph.D., Chairman of the Board and CEO, said: "On behalf of the Board, I wish to thank Tom for his many years of dedicated service to the company and its key

TransCode Therapeutics CFO Tom Fitzgerald retires, replaced interim

Thu, 10 Sep 2026 16:13:02 -0400

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced the retirement of Chief Financial Officer Tom Fitzgerald, effective immediately, with John Tattory named as Interim Chief Financial Officer.

Philippe P. Calais, Ph.D., Chairman of the Board and CEO, said: "On behalf of the Board, I wish to thank Tom for his many years of dedicated service to the company and its key

TransCode Therapeutics Announces Leadership Transition

Thu, 10 Sep 2026 16:10:00 -0400

Tom Fitzgerald, Chief Financial Officer, Announces his Retirement

John Tattory, to become Interim Chief Financial Officer

BOSTON, Sept. 10, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced the retirement of its Chief Financial Officer, Tom Fitzgerald. Mr. Fitzgerald has served as the Chief Financial Officer of TransCode Therapeutics since July 2018, during which time he helped lead the company through its initial public offering, the launch of its clinical program

TransCode Therapeutics Announces Leadership Transition

Thu, 10 Sep 2026 16:10:00 -0400

Tom Fitzgerald, Chief Financial Officer, Announces his Retirement

John Tattory, to become Interim Chief Financial Officer

TransCode Therapeutics Announces Leadership Transition

Thu, 10 Sep 2026 16:10:00 -0400

Tom Fitzgerald, Chief Financial Officer, Announces his Retirement

John Tattory, to become Interim Chief Financial Officer

TransCode Therapeutics Announces Leadership Transition

Thu, 10 Sep 2026 16:10:00 -0400

Tom Fitzgerald, Chief Financial Officer, Announces his Retirement

John Tattory, to become Interim Chief Financial Officer

Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer

Thu, 03 Sep 2026 09:00:00 -0400

Learn how TransCode Therapeutics is advancing RNA therapeutics, cancer vaccines, and immuno-oncology programs designed to address advanced and metastatic cancers

Management to discuss TTX-MC138, the ongoing Phase 2a colorectal cancer trial, tumor-targeted RNA delivery, and multiple upcoming clinical catalysts

ORLANDO, FL / ACCESS Newswire / September 3, 2026 / RedChip Companies will host an investor webinar on Wednesday, September 16, 2026, at 4:15 p.m. ET with TransCode Therapeutics, Inc. (NASDAQ:RNAZ). The webinar is free to attend and open to all.

The exclusive event will feature Philippe P. Calais Ph.D., Chairman and CEO; Zdravka Medarova,

Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer

Thu, 03 Sep 2026 09:00:00 -0400

Learn how TransCode Therapeutics is advancing RNA therapeutics, cancer vaccines, and immuno-oncology programs designed to address advanced and metastatic cancers

Management to discuss TTX-MC138, the ongoing Phase 2a colorectal cancer trial, tumor-targeted RNA delivery, and multiple upcoming clinical catalysts

The exclusive event will feature Philippe P. Calais Ph.D., Chairman and CEO; Zdravka Medarova,

Form 10-Q Transcode Therapeutics, For: Jun 30

Fri, 14 Aug 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260814/26932600.html

Form 10-Q Transcode Therapeutics, For: Jun 30

Fri, 14 Aug 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260814/26932600.html

Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

Fri, 07 Aug 2026 09:00:00 -0400

ORLANDO, FL / ACCESS Newswire / August 7, 2026 / RedChip Companies will air interviews with Virax Biolabs Group Ltd. (Nasdaq:VRAX) and Transcode Therapeutics Inc. (Nasdaq:RNAZ) on the RedChip Small Stocks, Big Money™ show, a sponsored television program airing on Bloomberg TV this Saturday, August 8, at 7:00 p.m. Eastern Time (ET), and on CNBC this Sunday, August 9, at 11:00 a.m. ET. Bloomberg TV is available in an estimated 73 million homes across the United States, and CNBC is available in approximately 90 million U.S. households.

Access the interviews in their entirety

Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

Fri, 07 Aug 2026 09:00:00 -0400

ORLANDO, FL / ACCESS Newswire / August 7, 2026 / RedChip Companies will air interviews with Virax Biolabs Group Ltd. (Nasdaq:VRAX) and Transcode Therapeutics Inc. (Nasdaq:RNAZ) on the RedChip Small Stocks, Big Money™ show, a sponsored television program airing on Bloomberg TV this Saturday, August 8, at 7:00 p.m. Eastern Time (ET), and on CNBC this Sunday, August 9, at 11:00 a.m. ET. Bloomberg TV is available in an estimated 73 million homes across the United States, and CNBC is available in approximately 90 million U.S. households.
Access the interviews in their entirety

Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

Fri, 07 Aug 2026 09:00:00 -0400

ORLANDO, FL / ACCESS Newswire / August 7, 2026 / RedChip Companies will air interviews with Virax Biolabs Group Ltd. (Nasdaq:VRAX) and Transcode Therapeutics Inc. (Nasdaq:RNAZ) on the RedChip Small Stocks, Big Money™ show, a sponsored television program airing on Bloomberg TV this Saturday, August 8, at 7:00 p.m. Eastern Time (ET), and on CNBC this Sunday, August 9, at 11:00 a.m. ET. Bloomberg TV is available in an estimated 73 million homes across the United States, and CNBC is available in approximately 90 million U.S. households.
Access the interviews in their entirety

Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

Fri, 07 Aug 2026 09:00:00 -0400

ORLANDO, FL / ACCESS Newswire / August 7, 2026 / RedChip Companies will air interviews with Virax Biolabs Group Ltd. (Nasdaq:VRAX) and Transcode Therapeutics Inc. (Nasdaq:RNAZ) on the RedChip Small Stocks, Big Money™ show, a sponsored television program airing on Bloomberg TV this Saturday, August 8, at 7:00 p.m. Eastern Time (ET), and on CNBC this Sunday, August 9, at 11:00 a.m. ET. Bloomberg TV is available in an estimated 73 million homes across the United States, and CNBC is available in approximately 90 million U.S. households.
Access the interviews in their entirety

Form 4 Transcode Therapeutics, For: Aug 03 Filed by: CK Life Sciences Intl (Holdings) Inc

Wed, 05 Aug 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260805/26873985.html

Form 4 Transcode Therapeutics, For: Aug 03 Filed by: CK Life Sciences Intl (Holdings) Inc

Wed, 05 Aug 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260805/26873985.html

Form 3 Transcode Therapeutics, For: Jul 27 Filed by: CK Life Sciences Intl (Holdings) Inc

Wed, 05 Aug 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260805/26873932.html

Form 3 Transcode Therapeutics, For: Jul 27 Filed by: CK Life Sciences Intl (Holdings) Inc

Wed, 05 Aug 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260805/26873932.html

Form SCHEDULE 13D/A Transcode Therapeutics, Filed by: CK Life Sciences Intl (Holdings) Inc

Mon, 03 Aug 2026 16:39:00 -0400
si-local-file:///var/storage/secattach/20260803/26858740.html